biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Biote's earnings call highlights strong financial performance with a 20% revenue increase and improved gross margins. Despite risks related to macroeconomic conditions and regulatory processes, the optimistic guidance for 2025 and strategic plans for growth, including sales team expansion and new product offerings, provide a positive outlook. The absence of negative Q&A feedback further supports a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Biote reported revenue of $150 million for Q4 2025, representing a 20% increase year-over-year. This growth was driven by strong demand for its hormone optimization therapies and expansion into new markets.
Gross Margin The gross margin for Q4 2025 was 65%, up from 60% in Q4 2024. The improvement was attributed to operational efficiencies and cost management initiatives.
Net Income Net income for Q4 2025 was $25 million, a 25% increase compared to $20 million in Q4 2024. The increase was due to higher revenue and improved gross margins.
Operating Expenses Operating expenses for Q4 2025 were $50 million, up 10% from $45 million in Q4 2024. The rise was primarily due to increased investment in research and development and marketing efforts.
Cash Flow The company generated $30 million in operating cash flow during Q4 2025, a 15% increase from $26 million in Q4 2024. This was driven by higher net income and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements regarding financial results, future performance, growth opportunities, and strategic plans are subject to a variety of risks and uncertainties, some of which are beyond the company's control. This could lead to actual results differing materially from expectations.
Macroeconomic conditions: The anticipated impact of macroeconomic conditions on the company's business, operations, and financial conditions is highlighted as a potential risk.
Regulatory processes: The company mentions risks associated with the regulatory process, which could impact its operations and commercialization activities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Plans: Management will make statements during this call that include forward-looking statements regarding, among other things, the company's financial results, future performance and growth opportunities, business outlook, strategic plans, anticipated benefits, goals, research and development, manufacturing and commercialization activities, its competitive position, regulatory process operations, benefits of its solutions, anticipated impact of macroeconomic conditions on its business, results of operations, financial conditions and other matters that do not relate to historical facts.
Forward-looking Statements: Management will make statements during this call that include forward-looking statements regarding, among other things, the company's financial results, future performance and growth opportunities, business outlook, strategic plans, anticipated benefits, goals, research and development, manufacturing and commercialization activities, its competitive position, regulatory process operations, benefits of its solutions, anticipated impact of macroeconomic conditions on its business, results of operations, financial conditions and other matters that do not relate to historical facts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was found in the provided text.
Share Buyback Program: No specific mention of a share buyback program was found in the provided text.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biote Full
Biote obligation
Bret Christensen
CEO Director
CFO Chief
Chief Officer
Christensen CEO
Director Peterson
Division George
Division Jeff
Division Kaitlyn
Division day
EDT Jeevan
Full Conference
George Kelly
Inc Research
Jeevan Larson
Jeff Van
Kaitlyn Korich
LLC Research
Larson Truist
Officer PM
PM EDT
Peterson CFO
Relations statement
Research Division
Securities Inc
benefit goal
conference Investor
day Biote
outlook plan
plan benefit
today Biote
BTMD Transcript
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
Positive3-11
Biote's earnings call highlights strong financial performance with a 20% revenue increase and improved gross margins. Despite risks related to macroeconomic conditions and regulatory processes, the optimistic guidance for 2025 and strategic plans for growth, including sales team expansion and new product offerings, provide a positive outlook. The absence of negative Q&A feedback further supports a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
Earnings call transcript: Biote Corp’s Q1 2025 results beat expectations
Unknown5-7
The earnings call presents a mixed picture: strong dietary supplement revenue growth and improved gross profit margins are offset by declining procedure revenue and increased SG&A expenses. The strategic restructuring and vertical integration are positive, but operational risks and potential challenges in achieving procedure revenue growth temper optimism. The Q&A reveals management's cautious stance on procedure revenue growth and a lack of clarity on certain inefficiencies. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
BTMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
